Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range. Existing shareholder ARK Investment Management and new investor...read more
While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead. RNA interference biotech City Therapeutics (CTY) plans to raise $175 million at a $1.0 billion...read more
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, announced terms for its IPO on Thursday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 ...read more
One IPO and two SPACs debuted this week, although more deals were originally on the calendar. Five IPOs and three SPACs submitted initial filings. The biggest story in the IPO market this week may be the deals that didn’t get done. Homeowners insurance...read more
Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, raised $150 million by offering 9.4 million shares at $16, within the $15 to $17 range. Existing shareholder ARK Investment Management and new investor...read more
US IPO Week Ahead: Biotech remains a bright spot in a 2 IPO week
While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead. RNA interference biotech City Therapeutics (CTY) plans to raise $175 million at a $1.0 billion...read more
Small molecule biotech Iambic Therapeutics sets terms for $150 million IPO
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, announced terms for its IPO on Thursday. The San Diego, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 ...read more
US IPO Weekly Recap: Postponed deals put damper on fall IPO market
One IPO and two SPACs debuted this week, although more deals were originally on the calendar. Five IPOs and three SPACs submitted initial filings. The biggest story in the IPO market this week may be the deals that didn’t get done. Homeowners insurance...read more